Legal & General Group Plc Acquires 10,847 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Legal & General Group Plc lifted its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 3.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 352,700 shares of the company's stock after acquiring an additional 10,847 shares during the period. Legal & General Group Plc owned 0.76% of Omnicell worth $15,702,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Smartleaf Asset Management LLC grew its stake in Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after acquiring an additional 273 shares during the period. Van ECK Associates Corp lifted its position in Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after acquiring an additional 315 shares in the last quarter. Headlands Technologies LLC bought a new stake in Omnicell during the fourth quarter worth $53,000. First Horizon Advisors Inc. raised its position in Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after buying an additional 355 shares during the last quarter. Finally, Huntington National Bank raised its position in Omnicell by 236.4% in the 4th quarter. Huntington National Bank now owns 1,359 shares of the company's stock valued at $61,000 after buying an additional 955 shares during the last quarter. Institutional investors own 97.70% of the company's stock.

Omnicell Price Performance

OMCL traded down $0.67 during trading on Friday, reaching $30.28. The stock had a trading volume of 727,408 shares, compared to its average volume of 532,862. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The business has a 50-day moving average of $35.27 and a 200-day moving average of $41.27. Omnicell, Inc. has a one year low of $25.12 and a one year high of $55.75. The stock has a market cap of $1.42 billion, a PE ratio of 112.15, a PEG ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, equities research analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

OMCL has been the subject of several recent analyst reports. JPMorgan Chase & Co. reduced their target price on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research note on Thursday, March 20th. StockNews.com upgraded shares of Omnicell from a "hold" rating to a "buy" rating in a research note on Tuesday. Benchmark restated a "buy" rating and issued a $62.00 target price on shares of Omnicell in a research note on Tuesday, February 4th. Bank of America decreased their price target on Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research report on Monday, January 6th. Finally, Wells Fargo & Company dropped their price target on Omnicell from $40.00 to $38.00 and set an "equal weight" rating on the stock in a report on Thursday. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Omnicell has a consensus rating of "Hold" and an average target price of $50.67.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.